{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"114","value":"392"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"437"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"170","value":"454"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"465"}],"units":"Participants"}],"description":"Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"}],"paramType":"MEAN","populationDescription":"The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm","type":"SECONDARY","unitOfMeasure":"mcg/mL"}